Jazz Pharmaceuticals highlighted the US commercial launch of Ziihera (zanidatamab-hrii) for first-line HER2-positive advanced gastroesophageal adenocarcinoma.
Label supports use with fluoropyrimidine-platinum chemotherapy with tislelizumab for IHC 3+ or IHC 2+/ISH+ disease, regardless of PD-L1 status.
Median overall survival was 26.4 months for Ziihera-chemotherapy-tislelizumab versus 19.2 months for trastuzumab-chemotherapy; p=0.0043.
Median progression-free survival was 12.4 months versus 8.1 months; objective response rate was 67% versus 63%.
Presentation reiterated a $3 billion-$5 billion peak sales opportunity for zanidatamab across gastroesophageal, biliary tract, breast, and other HER2-expressing cancers.
JAZZ•
